Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NUC-7738 by NuCana for Metastatic Melanoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
NUC-7738 by NuCana for Lymphoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs...
NUC-7738 by NuCana for Solid Tumor: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
NUC-7738 by NuCana for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase...
NUC-7738 by NuCana for Lung Adenocarcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
NUC-7738 by NuCana for Renal Cell Carcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
NUC-7738 by NuCana for T-Cell Lymphomas: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II...
NUC-7738 by NuCana for Chordoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...
NUC-7738 by NuCana for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...